Open AccessDrug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
Author(s) -
Shiv Gautam,
Parth Singh Meena
Publication year - 2011
Publication title -
indian journal of psychiatry/indian journal of psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.485
H-Index - 34
eISSN - 1998-3794
pISSN - 0019-5545
DOI - 10.4103/0019-5545.82537
Subject(s) - schizophrenia (object oriented programming) , drug , medicine , psychiatry , antipsychotic drug , metabolic syndrome , antipsychotic , obesity
Persons with schizophrenia are reported to be more likely to die from cardiovascular illness than those in the general population, and are at a greater risk of developing obesity, diabetes type 2, hypertension and dyslipidemias. Antipsychotic drugs used in the treatment of schizophrenia and other psychotic illnesses can induce weight gain, with some agents having a greater propensity to do so than others. These adverse effects associated with second-generation antipsychotics are also part of the metabolic syndrome.